微医控股三闯港交所：净利连亏三年，毛利率波动大且呈下降趋势

Core Viewpoint - WeDoctor Holdings Limited is progressing with its IPO application on the Hong Kong Stock Exchange, having updated its prospectus and disclosed its latest performance up to June 30, 2025, marking its third attempt to go public [1] Business Overview - WeDoctor primarily operates in two core business areas: AI medical services and online-offline medical services. The AI medical services rely on a bundled payment model based on contracted personnel, while the online-offline medical services have evolved from a free online appointment system to a comprehensive healthcare service for individuals and corporate clients [2] Financial Performance - The company has experienced significant revenue growth from 2022 to 2024, with a remarkable increase of 195.1% in 2024 compared to 2023. However, it has faced continuous net losses, with a net loss rate of 30.5% in 2024. The losses are attributed to increased fair value losses on financial instruments issued to investors and rising costs during business expansion [3][6] - In the first half of 2025, the company achieved a revenue of 3.08 billion RMB, a year-on-year increase of 69.4%. The adjusted loss rate from ongoing operations narrowed from 7.0% in the same period last year to 4.2%, indicating a move towards breakeven, and the operating cash flow turned positive for the first time [3] Profitability Metrics - The company's gross margin has shown volatility across its business segments. The health management membership service's profit margin fluctuated significantly, dropping from -24.1% in 2022 to 1.9% in 2024. The online medical service's gross margin decreased to 14.4% in 2023 due to physician compensation issues but rebounded to 16.9% in 2024 [4][5] - The net profit margin has remained negative, with figures of -276.1% in 2022, -79.3% in 2023, and -30.5% in 2024, reflecting weak profitability [6] Revenue Composition - The company's revenue composition is diverse, with health management membership services significantly increasing their share in 2024 and the first half of 2025. This indicates successful development in this area but also highlights a high dependency on a single segment, which poses risks if issues arise in that sector [7][8] Financial Challenges - Despite revenue growth, the company faces financial difficulties, including ongoing losses and high leverage. As of June 30, 2025, the company reported a net debt of approximately 25.3 billion RMB and a net current liability of 25.8 billion RMB, indicating significant leverage pressure [9] - The company relies heavily on three main customer types: local medical insurance funds, corporate clients, and individual users. The largest customer contributed 70.8% of revenue in 2024, increasing to 77.6% in the first half of 2025, which raises concerns about revenue concentration risk [10]